![]() | ![]() |
Formats:
|
||||||||||||||||
Copyright © 2006, American Society for Microbiology A Small Loop in the Capsid Protein of Moloney Murine Leukemia Virus Controls Assembly of Spherical Cores Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, New York 10032,1 Integrated Program in Cellular, Molecular, and Biophysical Studies, Columbia University College of Physicians and Surgeons, New York, New York 100322 *Corresponding author. Mailing address: Department of Pathology, Columbia University Medical Center, 630 West 168th Street, New York, NY 10032. Phone: (212) 305-4263. Fax: (212) 305-4189. E-mail: is132/at/columbia.edu. †Present address: Harvard Medical School, Boston, MA 02115. Received October 4, 2005; Accepted December 27, 2005. This article has been cited by other articles in PMC.Abstract We report the identification of a novel domain in the Gag protein of Moloney murine leukemia virus (MoLV) that is important for the formation of spherical cores. Analysis of 18 insertional mutations in the N-terminal domain of the capsid protein (CA) identified 3 that were severely defective for viral assembly and release. Transmission electron microscopy of cells producing these mutants showed assembly of Gag proteins in large, flat or dome-shaped patches at the plasma membrane. Spherical cores were not formed, and viral particles were not released. This late assembly/release block was partially rescued by wild-type virus. All three mutations localized to the small loop between α-helices 4 and 5 of CA, analogous to the cyclophilin A-binding loop of human immunodeficiency virus type 1 CA. In the X-ray structure of the hexameric form of MLV CA, this loop is located at the periphery of the hexamer. The phenotypes of mutations in this loop suggest that formation of a planar lattice of Gag is unhindered by mutations in the loop. However, the lack of progression of these planar structures to spherical ones suggests that mutations in this loop may prevent formation of pentamers or of stable pentamer-hexamer interactions, which are essential for the formation of a closed, spherical core. This region in CA, focused to a few residues of a small loop, may offer a novel therapeutic target for retroviral diseases. Retroviral assembly is remarkable among enveloped viruses. A single viral gene product, the Gag protein, is both necessary and sufficient to direct the assembly and release of virus-like particles from the host cell. During or shortly after viral release, Gag protein is cleaved by viral protease (PR) to yield three mature proteins common to all retroviruses: MA, CA, and NC. Most retroviruses contain one or more other proteins that differ in size and function in different retroviruses (13, 42). MA associates with the membrane, NC associates with the RNA genome, and CA forms a shell around the NC-RNA complex. Located in these Gag proteins are at least three elements known to participate in retroviral assembly and release. The M (membrane-binding) domain consists of a myristate moiety together with several basic residues in the N terminus of MA and targets newly synthesized Gag proteins to the plasma membrane (11, 38). The I (interaction) domain in NC allows Gag proteins to associate with each other. The L (late) domain is a small motif that varies in location and sequence in different retroviruses (e.g., PPPY in p12 of Moloney murine leukemia virus [MoMLV] and PTAPP in p6 of human immunodeficiency virus type 1 [HIV-1]) and is essential for the final pinching off of the membrane during viral release from the host cell (14). Here we describe the identification of a novel assembly region that is distinct from these well-characterized assembly and release domains and is located in the N-terminal domain (NTD) of MoMLV CA. Retroviral CA proteins play a crucial yet incompletely understood role in core assembly and viral release. Although there is little sequence similarity between CA proteins from different retroviruses, their secondary and tertiary structures appear to be remarkably well conserved (7, 35). During assembly the CA domain is thought to mediate Gag-Gag interactions (16, 18, 28, 35, 47). The precise nature of Gag interactions in immature particles is not known. For mature particles, the CA lattice has been modeled on X-ray structures and on cryoelectron microscopy reconstruction of CA assemblies that were generated in vitro or purified from mature virions (6, 18, 31). The model suggests that six CA NTDs form a hexagonal ring, and each ring is connected to six neighboring rings by a dimer interface between two CA C-terminal domains (CTDs), thus forming a hexameric lattice. Biochemical and genetic analysis of several retroviruses (MoMLV, Rous sarcoma virus [RSV] and HIV-1) suggest that CTDs play an important role in core assembly (10, 47). For HIV-1, the NTD is important for proper core formation and early steps following entry (37, 39, 43, 44, 46). For the NTD of MoMLV, few genetic or biochemical analyses have been performed. The recent determination of the structure of hexameric MLV CA NTD at 1.9-Å resolution (35) facilitates mutational analyses, such as this one. We recently used genetic footprinting to analyze a portion of the MoMLV gag gene (2). We found that a 12-amino-acid insertion anywhere in the first 77 amino acids of the N-terminal region of CA resulted in nonviable virus, suggesting that the NTD plays an essential role in MoMLV replication. This was in contrast to the C-terminal half of MA and all of p12, where over 75% of read-through insertions resulted in viable virus. We report here the analysis of 18 mutants in the NTD of CA to further understand its role in MoMLV replication. We found that three of these mutants were severely defective for core assembly and viral release. Transmission electron microscopy (TEM) of cells producing these mutants showed assembly of Gag protein in large, flat or dome-shaped patches at the plasma membrane, without the assembly of spherical cores and without particle release. These three mutations were localized to the small loop between α-helices 4 and 5 of CA located at the periphery of the CA hexamer (35). Mutant phenotypes suggest that the insertions do not hinder the formation of a stable, planar Gag lattice. The insertions may, however, prevent the formation of pentamers or their incorporation into the lattice, both of which are essential to generate the curvature necessary to convert a planar hexagonal lattice to a sphere. MATERIALS AND METHODS Plasmids and mutagenesis. Our mutagenesis of MoMLV gag has been described in detail elsewhere (2, 40). Individual clones were screened for mutations in the NTD of CA using PCR. One primer (short G, 5′-GGCCGCGTGCAGCTTTCA) complementary to a portion of the insertion and a second primer (2366L, 5′-TTTCTTCCGGGGTTTCTCGTTT) that hybridized outside the region of mutagenesis resulted in PCR products whose lengths depended upon the location of the insertion. Insertions in the NTD resulted in products of ≤650 bp; 15 such mutants were analyzed further. Three mutants in this study (see Fig. Fig.1,1
Amino acid insertion sequences for the three late mutants are as follows: 1955, VKAARGRVQLSG, located between amino acids G81 and D82; 1968, ESCTRPRAAFSP, between amino acids P86 and T87; and 1970, MKAARGRVQLSP, between P86 and T87. The insertions in mutants 1968 and 1970 were located between different nucleotides within the same codon, resulting in different sequences due to differing reading frames. Both mutants showed similar phenotypes, suggesting there was no correlation between insertion sequence and phenotype. High levels of viral protein production are important to visualize virion production by TEM. Late CA mutants, plus two mutants that flanked this region, were cloned into pNCS, a version of pNCA that contains a simian virus 40 origin of replication, permitting high levels of viral protein expression in 293T cells (19). Experiments were performed with pNCS and pNCA to ensure that the mutant phenotype was unaffected by expression levels. Control DNAs for cotransfection experiments consisted of pcDNA (Invitrogen), pCMS-EGFP (Clontech), and salmon sperm DNA (Invitrogen). A protease-deficient mutant, PR(-), containing the D32L change at residue 32, was produced in wild-type (WT) pNCS and in the three release-defective CA mutants by changing nucleotides GA to CT at positions 2765 and 2766, using primers 5′CGTACCTTCCTGGTACTTACTGGGGCCCAACAC and 5′GTGTTGGGCCCCAGTAAGTACCAGGAAGGTGACG (QuikChange II site-directed mutagenesis kit; Stratagene). All PR(-) clones were sequenced, and the PR(-) phenotype was confirmed by Western blotting. Cells, transfection, and infection. 293T cells and Rat2 cells were maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum, l-glutamine (2.2 mM), penicillin (100 U/ml), and streptomycin (100 μg/ml). 293T cells were transfected with WT or mutant proviral DNA using LipofectAMINE Plus following the manufacturer's protocol (Invitrogen). pCMS-EGFP (Clontech) was included in transfections to verify that differences in virion production reflected true differences in phenotypes rather than variations in transfection efficiencies. Supernatants were harvested 24, 48, and 72 h after transfection, spun to pellet virions, quantified using reverse transcriptase (RT) assays, and used to infect Rat2 cells (45). Infected Rat2 cells were passaged 2 to 3 days for 10 days. Virion release was monitored by RT assays. Virus purification and Western blot analysis. Culture supernatants were collected 48 h after transfection of 293T cells with proviral DNAs and centrifuged through 20% sucrose cushions, and pellets were resuspended in TN buffer (for RT assay) or RIPA buffer (for Western blotting) (45). Details of virus purification, lysis, and Western blot analysis were as described previously (45, 54). Goat anti-CA serum (NCI serum 79S-804; gift of S. P. Goff, Columbia University), diluted 1:5,000, was used for Western blot assays. Cell lysate blots were reprobed with rat antitubulin antibody (Pierce). Amounts of Gag protein were measured using densitometry and ImageQuant (Molecular Dynamics). Transmission electron microscopy of 293T cells transfected with proviral DNA. 293T cells plated on 35-mm dishes (Corning 430165) and transfected with proviral DNA were fixed 24 h posttransfection using 2.5% glutaraldehyde in 0.1 M Sorenson's buffer (0.1 M H2PO4, 0.1 M HPO4, pH 7.2) for at least 12 h. Samples were postfixed with 1% OsO4 in 0.1 M Sorenson's buffer for 1 h. Enblock staining using 1% tannic acid in water was followed by washing and staining with 1% uranyl acetate (23). After dehydration through an ethanol series, cells were embedded in Lx-112 (Ladd Research Industries, Inc). Sections of 60 nm were cut on an MT-7000 RMC apparatus, placed on mesh copper grids (Electron Microscope Sciences), stained with 1% uranyl acetate and 0.4% lead citrate, and examined under a JEOL JEM-1200 EXII electron microscope. Pictures were taken on an ORCA-HR digital camera (Hamamatsu), and measurements were made using the AMT Image Capture Engine. Analysis of viral DNA synthesized in vivo. Virions used to infect Rat2 cells were treated with DNase I (Boehringer Mannheim) to remove plasmid DNA remaining from transfections (32). Low-molecular-weight DNA (25) from infected Rat2 cells was analyzed by PCR to detect reverse transcription products. The region of CA containing the insertion was amplified by the primers 1913U (5′-GAAAAACAACGGGTGCTCTTAG) and 2134L (5′-ATTGGGCCCTTGTGTTATTCCT). Products from mutant DNA were 36 bp larger and could easily be distinguished from the corresponding WT product on high-resolution agarose gels (ISC BioExpress). PCR conditions and rat mitochondrial DNA primers were as described elsewhere (2, 40). RESULTS Effects of insertions on particle production. Genetic footprinting analysis of MoMLV Gag proteins revealed that a 12-amino-acid insertion in the first 77 amino acids of CA resulted in nonviable virus, suggesting that this region plays an essential role in viral replication (2). We chose 18 mutants in this region for further analyses. Fifteen of the 18 selected mutants contained 12-amino-acid insertions, and the remaining three, generated from a separate mutagenesis, contained five-amino-acid insertions (Fig. (Fig.1).1 To test whether the CA mutants were affected in virion production, 293T cells were transfected with mutant proviral DNAs and virion release into the supernatant was measured by assaying for RT activity (45). Most mutants released near-WT levels of virus (RT activity, ~60 to 120% of WT), suggesting no significant block to particle release (Fig. (Fig.1B).1B
The N-terminal CA mutations were noninfectious. To investigate whether the mutant particles released from cells were capable of completing the replication cycle, released particles were assayed for infectivity. Equal amounts of virions from transfections (based on RT activity) were used to infect Rat2 cells. WT virus production peaked in 2 days. In contrast, all 18 CA mutants failed to display any RT activity even after 10 days in culture (Fig. (Fig.1C).1C Analysis of viral proteins produced by release-defective CA mutants. To determine whether the lack of virion release for the three CA mutants was due to lack of viral protein production, we examined levels of intracellular CA proteins in transfected cells. Figure Figure2A2A
We analyzed Gag proteins in the released virions by Western blot assays using an anti-CA antibody. The total amount of Gag in the supernatant was much lower for the release-defective mutants (10 to 15% of WT). The mutants contained significantly less mature CA and more unprocessed Gag intermediates compared to WT virions (Fig. (Fig.2B)2B The budding defect caused by a mutation in the HIV-1 late domain has been reported to be suppressed by inactivation of the viral protease (26). To test if a similar mechanism played a role with the CA-loop mutants, we generated protease-defective virions for each of our three mutants by replacing the active site residue (D32) of the viral protease with leucine (15). As expected for the PR(-) mutant with wild-type CA sequence [WT/PR(-)], processing of the Gag precursor into mature Gag proteins was abolished (Fig. (Fig.2A,2A TEM analysis of CA mutants. We proceeded to examine why release of mutant virions from cells was blocked, despite sufficient viral protein synthesis and processing. Indirect immunofluorescence experiments using anti-CA antibody to visualize viral protein in transfected cells with proviral DNA did not show significant differences in the intracellular localization of mutant CA protein (data not shown). We therefore used TEM to examine thin sections of cells transfected with proviral DNA (Fig. (Fig.3).3
The electron-dense patches at the plasma membrane had a consistent and characteristic curvature for each mutant. Mutants 1955 and 1970 showed larger patches (200 to 400 nm) with less curvature (radii, 150 to 400 nm). Mutant 1968 showed smaller (100 nm) and more curved patches (radii, 100 to 120 nm). These differences may represent slightly different Gag superstructures assembled by each mutant. Thus, mutant Gag proteins assembled at the plasma membrane in large, dome-shaped patches and appeared incapable of assuming the spherical shape normally associated with MoMLV cores. Unlike intermediate stages of WT core assembly, which were rarely seen, these patches were abundant, suggesting that they might be long-lived and unable to progress to budding virions. Complementation of CA mutants by WT CA. To gain further insight into the mechanism of block in core assembly, we performed complementation experiments (Fig. (Fig.4).4
Virions released from cotransfected cells were analyzed by Western blotting. Mutant CA proteins, with their 12-amino-acid insertions, migrated slower than WT CA protein. Virions released from cotransfected cells clearly contained both WT and mutant CA proteins (Fig. (Fig.4B).4B TEM of cells producing both WT and mutant CA proteins. Cells cotransfected with WT and mutant proviral DNAs were examined by TEM. When equal amounts of WT and 1970 were used, virions were assembled and released at the plasma membrane (Fig. 4C and D Early stages of infection with mixed virions. When cells were transfected with mutant proviral DNA alone, the amounts of particles released were too small to determine if the mutants were functional for early steps of viral entry and replication. We therefore turned to the particles released from cells cotransfected with mixtures of WT and mutant proviral DNAs. As shown in Fig. Fig.4,4
To confirm that the CA mutant was able to undergo stages after reverse transcription, we looked for mutant CA protein following infection. Western blot analysis of infected Rat2 cell lysates indicated that mutant CA protein was synthesized (Fig. (Fig.5C).5C DISCUSSION Our previous mutational analysis of Gag protein mutants showed that the NTD of the MoMLV CA protein is remarkably intolerant of insertional mutations (2). We analyzed several NTD mutants in the current study and found that most were capable of core assembly and particle release. The exceptions were three mutations localized to the small loop between α-helices 4 and 5 of CA, corresponding to the cyclophilin A-binding loop in HIV-1 (Fig. (Fig.6).6 The conclusion that a Gag assembly element exists in the NTD of MoMLV CA disagrees with some HIV-1 CA studies that have indicated the NTD may not play an essential role in particle assembly (21). For example, HIV-1 Gag proteins lacking the NTD have been shown to assemble and bud from cells (1, 3). However, a series of substitution mutations in HIV-1 CA α-helices 4 to 6 (though none were in the loop) reduced particle production (47). One mutant in α-helix 4 showed electron-dense patches of Gag beneath the plasma membrane and lacked proper curvature (47), reminiscent of our MoMLV CA mutants. We speculate that the loop and surrounding α-helices may contribute to retroviral core assembly either directly by engaging in Gag-Gag interactions required for core formation or indirectly by binding a cellular factor necessary for efficient assembly and budding. Mature CA proteins from several retroviruses, including HIV-1 (18, 31), RSV (34), and MoMLV (17, 33, 52), form hexagonal lattices, akin to those formed by elemental carbon (20). The X-ray structure of the mature MLV CA NTD shows that NTDs assemble as hexamers, but it does not indicate how the hexamers assemble into a lattice (35). The exact time or site of hexamer assembly is not known. Since our mutants were defective for viral release, most of the Gag protein in cells expressing them was not proteolytically processed, and the lattice formed by such Gag precursors is not as well defined. It is also not clear if the protein-protein contacts formed in the immature CA lattice are retained in the mature core. However, in experiments where we rescued mutants with WT CA, we saw that the mixed virions contained mostly mature CA protein, both WT and mutant, allowing us to speculate on how such mutations might affect the hexagonal lattice structure. This is further aided by increasing evidence that immature Gag proteins also form hexagonal lattices during assembly. Electron cryomicroscopy of HIV-1 immature virions shows a hexagonal lattice (5), though unit cell dimensions of the CA hexamer in the lattice are smaller in immature virions than in mature virions (6). Also, in vitro assembly experiments utilizing MA-CA-NC domains from HIV-1 show hexameric arrangements similar to those in mature virions (27). These data suggest that factors that destabilize the hexagonal lattice in mature cores may also be applicable to immature cores. Thus, consideration of the high-resolution structure of the mature CA hexamer for mutants that do not form mature cores remains a useful method to understand the process of core assembly. Generating curvature within a planar lattice formed by hexamers requires the incorporation of pentamers (8). A total of 12 pentamers is required to create a closed object from a hexagonal lattice. The distribution of pentamers determines the curvature and shape of the object. The MoMLV core is spherical and could be created by distributing pentamers evenly throughout the lattice. There is little structural information on retroviral CA pentamers or how they interface with hexamers. We predict that these mutations prevent hexamer-pentamer interactions or disrupt the pentamer itself, thereby blocking spherical core formation. Little is known about the mechanism of spherical lattice assembly in other cellular systems. Mutational analysis of clathrin, which forms a hexagonal lattice interspersed with pentamers around vesicles involved in membrane traffic (12), has not revealed mutants with phenotypes analogous to ours (36). These retroviral CA mutations and their corresponding lattice defects may have general relevance to other spherical protein assemblies. An alternative possibility for lack of spherical cores that we were unable to rule out is that the insertions disrupt essential interactions between CA and other proteins (52). Such proteins could originate from the virus, e.g., MA or the cytoplasmic tail of Env, or from the host cell. For example, cyclophilin A binds the corresponding loop in HIV-1 but is not known to be involved in core formation. In support of a cellular factor binding this region, hydrogen-deuterium exchange experiments in the analogous area of HIV-1 (the cyclophilin A-binding loop and neighboring α-helices) displayed only a slight increase in hydrogen-deuterium exchange rate upon multimeric assembly of CA (29). This implies that the loop region does not form intramolecular protein-protein interactions, further suggesting it may bind a host factor or may be involved in intermolecular interactions (such as hexamer-hexamer or hexamer-pentamer interactions). Host cell proteins from the multivesicular body pathway are known to participate in viral budding (14). Dominant-negative mutations in multivesicular body proteins can inhibit membrane curvature and/or viral release in the case of several retroviruses (4, 41, 48), most likely through their interaction with the viral L domain protein. A protein that promotes membrane curvature during endocytosis, endophilin 2, is known to interact with MoMLV MA (49). It is possible that a similar interaction between host cell proteins and this loop in CA might also lead to membrane curvature. Interestingly, our TEM observations of the CA mutants were reminiscent of those of the human T-cell leukemia virus type 1 late (L) domain mutants, which form curved electron-dense thickenings underneath the plasma membrane (24, 30). These L-domain mutants are likely arrested at an earlier stage of budding than L-domain mutations described for other retroviruses, including MoMLV (14, 53), HIV-1 (22), Mason-Pfizer monkey virus (51), and RSV (50). The L-domain mutants from all of these retroviruses form particles containing complete spherical cores whose release from the budding site on the plasma membrane is impaired, keeping the cores joined to the cell and to each other by narrow stalks of plasma membrane. The striking overlaps between the two phenotypes suggest a possible association between the L-domain and the NTD of CA. In summary, we describe a novel function, i.e., the formation of spherical cores, for a domain in the NTD of MoMLV CA. This region is in the loop between α-helices 4 and 5 of CA, at the periphery of the NTD hexamer, and is essential for the progression of largely flat, multimeric Gag assembly intermediates to spheres. Since this region is localized to a small, structurally well-defined region in CA, it could serve as a potential target for antiretroviral therapy. Acknowledgments We thank Steve Goff for numerous helpful discussions and for the anti-CA antibody. We thank Fadila Bouamr for insightful discussions at the beginning of the project. We are grateful to Sam Stampfer for generating the figure with PyMol. We thank David Sayah, Harsh Thaker, Brett Lauring, and Steve Goff for valuable comments on the manuscript. REFERENCES 1. Accola, M. A., B. Strack, and H. G. Gottlinger. 2000. Efficient particle production by minimal Gag constructs which retain the carboxy-terminal domain of human immunodeficiency virus type 1 capsid-p2 and a late assembly domain. J. Virol. 74:5395-5402. [PubMed] 2. Auerbach, M. R., C. Shu, A. Kaplan, and I. R. Singh. 2003. Functional characterization of a portion of the Moloney murine leukemia virus gag gene by genetic footprinting. Proc. Natl. Acad. Sci. USA 100:11678-11683. [PubMed] 3. Borsetti, A., A. Ohagen, and H. G. Gottlinger. 1998. The C-terminal half of the human immunodeficiency virus type 1 Gag precursor is sufficient for efficient particle assembly. J. Virol. 72:9313-9317. [PubMed] 4. Bouamr, F., J. A. Melillo, M. Q. Wang, K. Nagashima, M. de Los Santos, A. Rein, and S. P. Goff. 2003. PPPYVEPTAP motif is the late domain of human T-cell leukemia virus type 1 Gag and mediates its functional interaction with cellular proteins Nedd4 and Tsg101 [corrected]. J. Virol. 77:11882-11895. [PubMed] 5. Briggs, J. A., M. N. Simon, I. Gross, H. G. Krausslich, S. D. Fuller, V. M. Vogt, and M. C. Johnson. 2004. The stoichiometry of Gag protein in HIV-1. Nat. Struct. Mol. Biol. 11:672-675. [PubMed] 6. Briggs, J. A., T. Wilk, R. Welker, H. G. Krausslich, and S. D. Fuller. 2003. Structural organization of authentic, mature HIV-1 virions and cores. EMBO J. 22:1707-1715. [PubMed] 7. Campos-Olivas, R., J. L. Newman, and M. F. Summers. 2000. Solution structure and dynamics of the Rous sarcoma virus capsid protein and comparison with capsid proteins of other retroviruses. J. Mol. Biol. 296:633-649. [PubMed] 8. Caspar, D. L., and A. Klug. 1962. Physical principles in the construction of regular viruses. Cold Spring Harbor Symp. Quant. Biol. 27:1-24. [PubMed] 9. DeLano, W. L. 2002. The PyMOL Molecular Graphics System, 0.98 ed. DeLano Scientific, San Carlos, Calif. 10. Dorfman, T., A. Bukovsky, A. Ohagen, S. Hoglund, and H. G. Gottlinger. 1994. Functional domains of the capsid protein of human immunodeficiency virus type 1. J. Virol. 68:8180-8187. [PubMed] 11. Facke, M., A. Janetzko, R. L. Shoeman, and H. G. Krausslich. 1993. A large deletion in the matrix domain of the human immunodeficiency virus gag gene redirects virus particle assembly from the plasma membrane to the endoplasmic reticulum. J. Virol. 67:4972-4980. [PubMed] 12. Fotin, A., Y. Cheng, N. Grigorieff, T. Walz, S. C. Harrison, and T. Kirchhausen. 2004. Structure of an auxilin-bound clathrin coat and its implications for the mechanism of uncoating. Nature 432:649-653. [PubMed] 13. Freed, E. O. 1998. HIV-1 gag proteins: diverse functions in the virus life cycle. Virology 251:1-15. [PubMed] 14. Freed, E. O. 2002. Viral late domains. J. Virol. 76:4679-4687. [PubMed] 15. Fu, W., and A. Rein. 1993. Maturation of dimeric viral RNA of Moloney murine leukemia virus. J. Virol. 67:5443-5449. [PubMed] 16. Gamble, T. R., F. F. Vajdos, S. Yoo, D. K. Worthylake, M. Houseweart, W. I. Sundquist, and C. P. Hill. 1996. Crystal structure of human cyclophilin A bound to the amino-terminal domain of HIV-1 capsid. Cell 87:1285-1294. [PubMed] 17. Ganser, B. K., A. Cheng, W. I. Sundquist, and M. Yeager. 2003. Three-dimensional structure of the M-MuLV CA protein on a lipid monolayer: a general model for retroviral capsid assembly. EMBO J. 22:2886-2892. [PubMed] 18. Ganser, B. K., S. Li, V. Y. Klishko, J. T. Finch, and W. I. Sundquist. 1999. Assembly and analysis of conical models for the HIV-1 core. Science 283:80-83. [PubMed] 19. Gao, G., and S. P. Goff. 1998. Replication defect of Moloney murine leukemia virus with a mutant reverse transcriptase that can incorporate ribonucleotides and deoxyribonucleotides. J. Virol. 72:5905-5911. [PubMed] 20. Ge, M., and K. Sattler. 1994. Observation of fullerene cones. Chem. Phys. Lett. 220:192-196. 21. Gottlinger, H. G. 2001. The HIV-1 assembly machine. AIDS 15(Suppl. 5):S13-S20. 22. Gottlinger, H. G., T. Dorfman, J. G. Sodroski, and W. A. Haseltine. 1991. Effect of mutations affecting the p6 gag protein on human immunodeficiency virus particle release. Proc. Natl. Acad. Sci. USA 88:3195-3199. [PubMed] 23. Hayat, M. A. 1989. Principles and techniques of electron microscopy, 3rd ed. CRC Press, Inc., Boca Raton, Fla. 24. Heidecker, G., P. A. Lloyd, K. Fox, K. Nagashima, and D. Derse. 2004. Late assembly motifs of human T-cell leukemia virus type 1 and their relative roles in particle release. J. Virol. 78:6636-6648. [PubMed] 25. Hirt, B. 1967. Selective extraction of polyoma DNA from infected mouse cell cultures. J. Mol. Biol. 26:365-369. [PubMed] 26. Huang, M., J. M. Orenstein, M. A. Martin, and E. O. Freed. 1995. p6Gag is required for particle production from full-length human immunodeficiency virus type 1 molecular clones expressing protease. J. Virol. 69:6810-6818. [PubMed] 27. Huseby, D., R. L. Barklis, A. Alfadhli, and E. Barklis. 2005. Assembly of human immunodeficiency virus precursor gag proteins. J. Biol. Chem. 280:17664-17670. [PubMed] 28. Kingston, R. L., T. Fitzon-Ostendorp, E. Z. Eisenmesser, G. W. Schatz, V. M. Vogt, C. B. Post, and M. G. Rossmann. 2000. Structure and self-association of the Rous sarcoma virus capsid protein. Struct. Fold Des. 8:617-628. 29. Lanman, J., T. T. Lam, S. Barnes, M. Sakalian, M. R. Emmett, A. G. Marshall, and P. E. Prevelige, Jr. 2003. Identification of novel interactions in HIV-1 capsid protein assembly by high-resolution mass spectrometry. J. Mol. Biol. 325:759-772. [PubMed] 30. Le Blanc, I., M. C. Prevost, M. C. Dokhelar, and A. R. Rosenberg. 2002. The PPPY motif of human T-cell leukemia virus type 1 Gag protein is required early in the budding process. J. Virol. 76:10024-10029. [PubMed] 31. Li, S., C. P. Hill, W. I. Sundquist, and J. T. Finch. 2000. Image reconstructions of helical assemblies of the HIV-1 CA protein. Nature 407:409-413. [PubMed] 32. Lim, D., M. Orlova, and S. P. Goff. 2002. Mutations of the RNase H C helix of the Moloney murine leukemia virus reverse transcriptase reveal defects in polypurine tract recognition. J. Virol. 76:8360-8373. [PubMed] 33. Mayo, K., D. Huseby, J. McDermott, B. Arvidson, L. Finlay, and E. Barklis. 2003. Retrovirus capsid protein assembly arrangements. J. Mol. Biol. 325:225-237. [PubMed] 34. Mayo, K., M. L. Vana, J. McDermott, D. Huseby, J. Leis, and E. Barklis. 2002. Analysis of Rous sarcoma virus capsid protein variants assembled on lipid monolayers. J. Mol. Biol. 316:667-678. [PubMed] 35. Mortuza, G. B., L. F. Haire, A. Stevens, S. J. Smerdon, J. P. Stoye, and I. A. Taylor. 2004. High-resolution structure of a retroviral capsid hexameric amino-terminal domain. Nature 431:481-485. [PubMed] 36. Payne, G. S. 1990. Genetic analysis of clathrin function in yeast. J. Membr. Biol 116:93-105. [PubMed] 37. Reicin, A. S., A. Ohagen, L. Yin, S. Hoglund, and S. P. Goff. 1996. The role of Gag in human immunodeficiency virus type 1 virion morphogenesis and early steps of the viral life cycle. J. Virol. 70:8645-8652. [PubMed] 38. Rein, A., M. R. McClure, N. R. Rice, R. B. Luftig, and A. M. Schultz. 1986. Myristylation site in Pr65gag is essential for virus particle formation by Moloney murine leukemia virus. Proc. Natl. Acad. Sci. USA 83:7246-7250. [PubMed] 39. Scholz, I., B. Arvidson, D. Huseby, and E. Barklis. 2005. Virus particle core defects caused by mutations in the human immunodeficiency virus capsid N-terminal domain. J. Virol. 79:1470-1479. [PubMed] 40. Singh, I. R., R. A. Crowley, and P. O. Brown. 1997. High-resolution functional mapping of a cloned gene by genetic footprinting. Proc. Natl. Acad. Sci. USA 94:1304-1309. [PubMed] 41. Strack, B., A. Calistri, S. Craig, E. Popova, and H. G. Gottlinger. 2003. AIP1/ALIX is a binding partner for HIV-1 p6 and EIAV p9 functioning in virus budding. Cell 114:689-699. [PubMed] 42. Swanstrom, R., and J. W. Wills. 1997. Synthesis, assembly, and processing of viral proteins, p. 263-334. In J. M. Coffin, S. H. Hughes, and H. E. Varmus (ed.), Retroviruses. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. 43. Tang, S., T. Murakami, B. E. Agresta, S. Campbell, E. O. Freed, and J. G. Levin. 2001. Human immunodeficiency virus type 1 N-terminal capsid mutants that exhibit aberrant core morphology and are blocked in initiation of reverse transcription in infected cells. J. Virol. 75:9357-9366. [PubMed] 44. Tang, S., T. Murakami, N. Cheng, A. C. Steven, E. O. Freed, and J. G. Levin. 2003. Human immunodeficiency virus type 1 N-terminal capsid mutants containing cores with abnormally high levels of capsid protein and virtually no reverse transcriptase. J. Virol. 77:12592-12602. [PubMed] 45. Telesnitsky, A., S. Blain, and S. P. Goff. 1995. Assays for retroviral reverse transcriptase. Methods Enzymol. 262:347-362. [PubMed] 46. von Schwedler, U. K., T. L. Stemmler, V. Y. Klishko, S. Li, K. H. Albertine, D. R. Davis, and W. I. Sundquist. 1998. Proteolytic refolding of the HIV-1 capsid protein amino-terminus facilitates viral core assembly. EMBO J. 17:1555-1568. [PubMed] 47. von Schwedler, U. K., K. M. Stray, J. E. Garrus, and W. I. Sundquist. 2003. Functional surfaces of the human immunodeficiency virus type 1 capsid protein. J. Virol. 77:5439-5450. [PubMed] 48. von Schwedler, U. K., M. Stuchell, B. Muller, D. M. Ward, H. Y. Chung, E. Morita, H. E. Wang, T. Davis, G. P. He, D. M. Cimbora, A. Scott, H. G. Krausslich, J. Kaplan, S. G. Morham, and W. I. Sundquist. 2003. The protein network of HIV budding. Cell 114:701-713. [PubMed] 49. Wang, M. Q., W. Kim, G. Gao, T. A. Torrey, H. C. Morse III, P. De Camilli, and S. P. Goff. 2003. Endophilins interact with Moloney murine leukemia virus Gag and modulate virion production. J. Biol. 3:4. [PubMed] 50. Wills, J. W., C. E. Cameron, C. B. Wilson, Y. Xiang, R. P. Bennett, and J. Leis. 1994. An assembly domain of the Rous sarcoma virus Gag protein required late in budding. J. Virol. 68:6605-6618. [PubMed] 51. Yasuda, J., and E. Hunter. 1998. A proline-rich motif (PPPY) in the Gag polyprotein of Mason-Pfizer monkey virus plays a maturation-independent role in virion release. J. Virol. 72:4095-4103. [PubMed] 52. Yeager, M., E. M. Wilson-Kubalek, S. G. Weiner, P. O. Brown, and A. Rein. 1998. Supramolecular organization of immature and mature murine leukemia virus revealed by electron cryo-microscopy: implications for retroviral assembly mechanisms. Proc. Natl. Acad. Sci. USA 95:7299-7304. [PubMed] 53. Yuan, B., S. Campbell, E. Bacharach, A. Rein, and S. P. Goff. 2000. Infectivity of Moloney murine leukemia virus defective in late assembly events is restored by late assembly domains of other retroviruses. J. Virol. 74:7250-7260. [PubMed] 54. Yuan, B., X. Li, and S. P. Goff. 1999. Mutations altering the Moloney murine leukemia virus p12 Gag protein affect virion production and early events of the virus life cycle. EMBO J. 18:4700-4710. [PubMed] |
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||
Virology. 1998 Nov 10; 251(1):1-15.
[Virology. 1998]J Virol. 1993 Aug; 67(8):4972-80.
[J Virol. 1993]Proc Natl Acad Sci U S A. 1986 Oct; 83(19):7246-50.
[Proc Natl Acad Sci U S A. 1986]J Virol. 2002 May; 76(10):4679-87.
[J Virol. 2002]J Mol Biol. 2000 Feb 18; 296(2):633-49.
[J Mol Biol. 2000]Nature. 2004 Sep 23; 431(7007):481-5.
[Nature. 2004]Cell. 1996 Dec 27; 87(7):1285-94.
[Cell. 1996]Science. 1999 Jan 1; 283(5398):80-3.
[Science. 1999]J Virol. 2003 May; 77(9):5439-50.
[J Virol. 2003]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]Nature. 2004 Sep 23; 431(7007):481-5.
[Nature. 2004]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 1997 Feb 18; 94(4):1304-9.
[Proc Natl Acad Sci U S A. 1997]J Virol. 1998 Jul; 72(7):5905-11.
[J Virol. 1998]Methods Enzymol. 1995; 262():347-62.
[Methods Enzymol. 1995]Methods Enzymol. 1995; 262():347-62.
[Methods Enzymol. 1995]EMBO J. 1999 Sep 1; 18(17):4700-10.
[EMBO J. 1999]J Virol. 2002 Aug; 76(16):8360-73.
[J Virol. 2002]J Mol Biol. 1967 Jun 14; 26(2):365-9.
[J Mol Biol. 1967]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]Proc Natl Acad Sci U S A. 1997 Feb 18; 94(4):1304-9.
[Proc Natl Acad Sci U S A. 1997]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]Methods Enzymol. 1995; 262():347-62.
[Methods Enzymol. 1995]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]J Virol. 1995 Nov; 69(11):6810-8.
[J Virol. 1995]J Virol. 1993 Sep; 67(9):5443-9.
[J Virol. 1993]J Virol. 2002 May; 76(10):4679-87.
[J Virol. 2002]Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7299-304.
[Proc Natl Acad Sci U S A. 1998]J Mol Biol. 1967 Jun 14; 26(2):365-9.
[J Mol Biol. 1967]Proc Natl Acad Sci U S A. 2003 Sep 30; 100(20):11678-83.
[Proc Natl Acad Sci U S A. 2003]J Virol. 2000 Jun; 74(12):5395-402.
[J Virol. 2000]J Virol. 1998 Nov; 72(11):9313-7.
[J Virol. 1998]J Virol. 2003 May; 77(9):5439-50.
[J Virol. 2003]Science. 1999 Jan 1; 283(5398):80-3.
[Science. 1999]Nature. 2000 Sep 21; 407(6802):409-13.
[Nature. 2000]J Mol Biol. 2002 Feb 22; 316(3):667-78.
[J Mol Biol. 2002]EMBO J. 2003 Jun 16; 22(12):2886-92.
[EMBO J. 2003]J Mol Biol. 2003 Jan 3; 325(1):225-37.
[J Mol Biol. 2003]Cold Spring Harb Symp Quant Biol. 1962; 27():1-24.
[Cold Spring Harb Symp Quant Biol. 1962]Nature. 2004 Dec 2; 432(7017):649-53.
[Nature. 2004]J Membr Biol. 1990 Jun; 116(2):93-105.
[J Membr Biol. 1990]Proc Natl Acad Sci U S A. 1998 Jun 23; 95(13):7299-304.
[Proc Natl Acad Sci U S A. 1998]J Mol Biol. 2003 Jan 24; 325(4):759-72.
[J Mol Biol. 2003]J Virol. 2002 May; 76(10):4679-87.
[J Virol. 2002]J Virol. 2003 Nov; 77(22):11882-95.
[J Virol. 2003]Cell. 2003 Sep 19; 114(6):689-99.
[Cell. 2003]Cell. 2003 Sep 19; 114(6):701-13.
[Cell. 2003]J Biol. 2003; 3(1):4.
[J Biol. 2003]Nature. 2004 Sep 23; 431(7007):481-5.
[Nature. 2004]